To aid in the prognostic classification of disease severity, we performed untargeted metabolomics profiling of 341 patients with plasma samples collected at six longitudinal time points. Using the temporal metabolic profiles and machine learning, we then built a predictive model of disease severity. We determined that the levels of 25 metabolites measured at the time of hospital admission successfully predict future disease severity.

The Cycle Threshold (CT) value in Real-time Polymerase Chain Reaction (RT-PCR) is where a target specific amplification signal becomes detectable and can infer viral load, risk of transmission and recovery in SARS-CoV-2 infections. Adoption into routine practice is however uncommon.

A total of 318 studies were retrieved, of which 49 were eligible, reporting on 16,272 pairs of nasopharyngeal/oropharyngeal and saliva samples. Meta-analysis showed high concordance, 92.6% (95%CI: 89.6-94.8), across studies and pooled sensitivities of 86.7% (95%CI: 83.5-89.3) and 92.2 (95%CI: 89.4-94.4) from saliva and nasopharyngeal/oropharyngeal swabs.

A spike in coronavirus disease 2019 (COVID-19) has occurred in Southern California since October 2020. Analysis of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Southern California prior to October indicated most isolates originated from clade 20C that likely emerged from New York via Europe early in the pandemic.

Based on SARS-CoV-2 genomes, we reconstruct a partial transmission tree of the early pandemic and coinfer the geographic location of ancestral lineages as well as the number of migration events into and between European regions. We find that the predominant lineage spreading in Europe during this time has a most recent common ancestor in Italy and was probably seeded by a transmission event in either Hubei, China or Germany.

Whole genome sequences were obtained for 30 HCWs and 20 patients. We found 7 sequence types in HCW and 11 in patients. Sequence Cluster A was the most predominant sequence type detected in 23 (77%) HCW, of whom 14 (74%) had direct patient contact and 9 (90%) with indirect patient contact. In addition, seven patients outside of the COVID-19 cohort isolation ward who became positive during their admission were infected with SARS-CoV-2 cluster A.

A total of 9?943?247 doses of the Pfizer-BioNTech vaccine and 7?581?429 doses of the Moderna vaccine were reported in the US. CDC identified 66 case reports received by VAERS that met Brighton Collaboration case definition criteria for anaphylaxis (levels 1, 2 or 3): 47 following Pfizer-BioNTech vaccine, for a reporting rate of 4.7 cases/million doses administered, and 19 following Moderna vaccine, for a rate of 2.5 cases/million doses administered.

Independent genomic surveillance programs based in New Mexico and Louisiana contemporaneously detected the rapid rise of numerous clade 20G (lineage B.1.2) infections carrying a Q677P substitution in S. The variant was first detected in the US on October 23, 2020.

For this cohort study, a total of 1808 asymptomatic participants were screened for SARS-CoV-2 using a CRISPR-based assay and a point-of-reference reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). The concordance between CRISPR-based and RT-qPCR testing suggests that CRISPR-based assays are reliable and offer alternative options for surveillance testing and detection of SARS-CoV-2 outbreaks, as is required to resume operations in higher-education institutions.

Alow-cost RT-PCR based "kit" was developed for faster turnaround than the CDC developed protocol. We demonstrated three detection workflows: two that can be deployed in laboratories conducting assays of variable complexity, and one that could be simple enough for point-of-care.

Among the 23 specimens collected during December 16–23, 22 (96%) were the B.1.351 variant. None of the 245 previously sequenced genomes was from this lineage. Among the 22 specimens containing the variant strain, 21 (95%) contained all nine B.1.351 lineage-defining mutations. Thirteen (57%) were from males, and the median patient age was 32 years.

The SARS-CoV-2 variant B.1.1.7 was identified in eight specimens from Minnesota residents, including six (19%) of the 31 specimens sequenced by MDH-PHL and two specimens sequenced through CDC’s national SARS-CoV-2 surveillance system.¶ The eight specimens were collected during December 18, 2020–January 11, 2021, from eight Minnesota residents in five counties.

We used documents submitted to the Food and Drug Administration2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose (Table 1). Even before the second dose, BNT162b2 was highly efficacious, with a vaccine efficacy of 92.6%

To aid in the prognostic classification of disease severity, we performed untargeted metabolomics profiling of 341 patients with plasma samples collected at six longitudinal time points. Using the temporal metabolic profiles and machine learning, we then built a predictive model of disease severity. We determined that the levels of 25 metabolites measured at the time of hospital admission successfully predict future disease severity.

The Cycle Threshold (CT) value in Real-time Polymerase Chain Reaction (RT-PCR) is where a target specific amplification signal becomes detectable and can infer viral load, risk of transmission and recovery in SARS-CoV-2 infections. Adoption into routine practice is however uncommon.

A total of 318 studies were retrieved, of which 49 were eligible, reporting on 16,272 pairs of nasopharyngeal/oropharyngeal and saliva samples. Meta-analysis showed high concordance, 92.6% (95%CI: 89.6-94.8), across studies and pooled sensitivities of 86.7% (95%CI: 83.5-89.3) and 92.2 (95%CI: 89.4-94.4) from saliva and nasopharyngeal/oropharyngeal swabs.

A spike in coronavirus disease 2019 (COVID-19) has occurred in Southern California since October 2020. Analysis of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Southern California prior to October indicated most isolates originated from clade 20C that likely emerged from New York via Europe early in the pandemic.

Based on SARS-CoV-2 genomes, we reconstruct a partial transmission tree of the early pandemic and coinfer the geographic location of ancestral lineages as well as the number of migration events into and between European regions. We find that the predominant lineage spreading in Europe during this time has a most recent common ancestor in Italy and was probably seeded by a transmission event in either Hubei, China or Germany.

Whole genome sequences were obtained for 30 HCWs and 20 patients. We found 7 sequence types in HCW and 11 in patients. Sequence Cluster A was the most predominant sequence type detected in 23 (77%) HCW, of whom 14 (74%) had direct patient contact and 9 (90%) with indirect patient contact. In addition, seven patients outside of the COVID-19 cohort isolation ward who became positive during their admission were infected with SARS-CoV-2 cluster A.

A total of 9?943?247 doses of the Pfizer-BioNTech vaccine and 7?581?429 doses of the Moderna vaccine were reported in the US. CDC identified 66 case reports received by VAERS that met Brighton Collaboration case definition criteria for anaphylaxis (levels 1, 2 or 3): 47 following Pfizer-BioNTech vaccine, for a reporting rate of 4.7 cases/million doses administered, and 19 following Moderna vaccine, for a rate of 2.5 cases/million doses administered.

Independent genomic surveillance programs based in New Mexico and Louisiana contemporaneously detected the rapid rise of numerous clade 20G (lineage B.1.2) infections carrying a Q677P substitution in S. The variant was first detected in the US on October 23, 2020.

For this cohort study, a total of 1808 asymptomatic participants were screened for SARS-CoV-2 using a CRISPR-based assay and a point-of-reference reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). The concordance between CRISPR-based and RT-qPCR testing suggests that CRISPR-based assays are reliable and offer alternative options for surveillance testing and detection of SARS-CoV-2 outbreaks, as is required to resume operations in higher-education institutions.

Alow-cost RT-PCR based "kit" was developed for faster turnaround than the CDC developed protocol. We demonstrated three detection workflows: two that can be deployed in laboratories conducting assays of variable complexity, and one that could be simple enough for point-of-care.

Among the 23 specimens collected during December 16–23, 22 (96%) were the B.1.351 variant. None of the 245 previously sequenced genomes was from this lineage. Among the 22 specimens containing the variant strain, 21 (95%) contained all nine B.1.351 lineage-defining mutations. Thirteen (57%) were from males, and the median patient age was 32 years.

The SARS-CoV-2 variant B.1.1.7 was identified in eight specimens from Minnesota residents, including six (19%) of the 31 specimens sequenced by MDH-PHL and two specimens sequenced through CDC’s national SARS-CoV-2 surveillance system.¶ The eight specimens were collected during December 18, 2020–January 11, 2021, from eight Minnesota residents in five counties.

We used documents submitted to the Food and Drug Administration2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose (Table 1). Even before the second dose, BNT162b2 was highly efficacious, with a vaccine efficacy of 92.6%

To aid in the prognostic classification of disease severity, we performed untargeted metabolomics profiling of 341 patients with plasma samples collected at six longitudinal time points. Using the temporal metabolic profiles and machine learning, we then built a predictive model of disease severity. We determined that the levels of 25 metabolites measured at the time of hospital admission successfully predict future disease severity.

The Cycle Threshold (CT) value in Real-time Polymerase Chain Reaction (RT-PCR) is where a target specific amplification signal becomes detectable and can infer viral load, risk of transmission and recovery in SARS-CoV-2 infections. Adoption into routine practice is however uncommon.

A total of 318 studies were retrieved, of which 49 were eligible, reporting on 16,272 pairs of nasopharyngeal/oropharyngeal and saliva samples. Meta-analysis showed high concordance, 92.6% (95%CI: 89.6-94.8), across studies and pooled sensitivities of 86.7% (95%CI: 83.5-89.3) and 92.2 (95%CI: 89.4-94.4) from saliva and nasopharyngeal/oropharyngeal swabs.

A spike in coronavirus disease 2019 (COVID-19) has occurred in Southern California since October 2020. Analysis of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) in Southern California prior to October indicated most isolates originated from clade 20C that likely emerged from New York via Europe early in the pandemic.

Based on SARS-CoV-2 genomes, we reconstruct a partial transmission tree of the early pandemic and coinfer the geographic location of ancestral lineages as well as the number of migration events into and between European regions. We find that the predominant lineage spreading in Europe during this time has a most recent common ancestor in Italy and was probably seeded by a transmission event in either Hubei, China or Germany.

Whole genome sequences were obtained for 30 HCWs and 20 patients. We found 7 sequence types in HCW and 11 in patients. Sequence Cluster A was the most predominant sequence type detected in 23 (77%) HCW, of whom 14 (74%) had direct patient contact and 9 (90%) with indirect patient contact. In addition, seven patients outside of the COVID-19 cohort isolation ward who became positive during their admission were infected with SARS-CoV-2 cluster A.

A total of 9?943?247 doses of the Pfizer-BioNTech vaccine and 7?581?429 doses of the Moderna vaccine were reported in the US. CDC identified 66 case reports received by VAERS that met Brighton Collaboration case definition criteria for anaphylaxis (levels 1, 2 or 3): 47 following Pfizer-BioNTech vaccine, for a reporting rate of 4.7 cases/million doses administered, and 19 following Moderna vaccine, for a rate of 2.5 cases/million doses administered.

Independent genomic surveillance programs based in New Mexico and Louisiana contemporaneously detected the rapid rise of numerous clade 20G (lineage B.1.2) infections carrying a Q677P substitution in S. The variant was first detected in the US on October 23, 2020.

For this cohort study, a total of 1808 asymptomatic participants were screened for SARS-CoV-2 using a CRISPR-based assay and a point-of-reference reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR). The concordance between CRISPR-based and RT-qPCR testing suggests that CRISPR-based assays are reliable and offer alternative options for surveillance testing and detection of SARS-CoV-2 outbreaks, as is required to resume operations in higher-education institutions.

Alow-cost RT-PCR based "kit" was developed for faster turnaround than the CDC developed protocol. We demonstrated three detection workflows: two that can be deployed in laboratories conducting assays of variable complexity, and one that could be simple enough for point-of-care.

Among the 23 specimens collected during December 16–23, 22 (96%) were the B.1.351 variant. None of the 245 previously sequenced genomes was from this lineage. Among the 22 specimens containing the variant strain, 21 (95%) contained all nine B.1.351 lineage-defining mutations. Thirteen (57%) were from males, and the median patient age was 32 years.

The SARS-CoV-2 variant B.1.1.7 was identified in eight specimens from Minnesota residents, including six (19%) of the 31 specimens sequenced by MDH-PHL and two specimens sequenced through CDC’s national SARS-CoV-2 surveillance system.¶ The eight specimens were collected during December 18, 2020–January 11, 2021, from eight Minnesota residents in five counties.

We used documents submitted to the Food and Drug Administration2 to derive the vaccine efficacy beginning from 2 weeks after the first dose to before the second dose (Table 1). Even before the second dose, BNT162b2 was highly efficacious, with a vaccine efficacy of 92.6%